docno,text,score
meta-llama_Llama-2-13b-chat-hf_116_multimedqa_10,"Prostate Cancer Outcomes Prostate cancer is a prevalent form of cancer that affects men over the age of 50. The disease has various outcomes depending on several factors such as the stage at which it was diagnosed, the treatment method employed, and the patient's overall health status. In this answer, we will explore the possible outcomes for patients with prostate cancer. Outcome #1: Curative Treatment When detected early, localized prostate cancer can be treated with curative intent using surgery or radiation therapy. These treatments aim to remove or destroy the tumor completely, leading to a cure. According to the American Cancer Society, if the cancer is confined within the prostate gland, the 5-year survival rate is nearly 98%. Outcome #2: Watchful Waiting For men with slow-growing, low-risk prostate cancer, doctors may recommend watchful waiting or active surveillance. This approach involves monitoring the patient's condition closely without immediate treatment. The goal is to avoid overtreating those with indolent cancer while still providing appropriate care for aggressive cases. Watchful waiting can lead to excellent long-term outcomes, but it requires frequent checkups and biopsies to monitor the cancer's progress. Outcome #3: Palliative Care If prostate cancer has spread to other parts of the body (metastatic), palliative care becomes the primary focus. The aim is to manage symptoms, improve quality of life, and prolong survival. Treatment options might include hormone therapy, chemotherapy, immunotherapy, or targeted therapies. While these interventions cannot cure metastatic prostate cancer, they can help alleviate pain, reduce swelling, and enhance the patient's wellbeing. Outcome #4: Recurrence After initial treatment, some patients experience a recurrence of their prostate cancer. This occurs when remaining cancer cells continue to grow and multiply despite previous treatment. Recurrences often happen years after the initial diagnosis and can be challenging to detect. Once identified, further treatment might be necessary to control the disease's growth and prevent complications. Outcome #5: Complications Prostate cancer can cause severe complications if left untreated or if the disease has advanced to later stages. Some potential issues include urinary in",-0.0045247077941894
chatgpt_116_multimedqa_3,"The outcome of prostate cancer can vary depending on various factors such as the stage of the cancer, the individual's overall health, and the treatment options chosen. In the early stages, when the cancer is localized to the prostate gland, the outlook is generally favorable. Many men with localized prostate cancer undergo treatment, such as surgery, radiation therapy, or active surveillance, and have a good chance of being cured or having long-term disease control. However, if prostate cancer is diagnosed at an advanced stage, where it has spread to other parts of the body, the prognosis may be less favorable. Treatment options for advanced prostate cancer focus on controlling the disease and managing symptoms, rather than aiming for a cure. In these cases, the goal is to extend life expectancy and improve quality of life. It's important to note that each case is unique, and outcomes can vary widely. It is advisable to consult with a healthcare professional who can provide personalized information based on individual circumstances and help determine the best course of action. Regular screenings and early detection are crucial for improving the chances of a favorable outcome.",-0.0050652273930609
d03d9000-019b-4e0d-b6af-6d0e7b029136,"© 2021 MJH Life Sciences and Cancer Network. All rights reserved. Clinical Consult: Assessing the Impact of Tailor X © 2021 MJH Life Sciences and Cancer Network. All rights reserved. CHICAGO-In 1994, the National Cancer Institute began a large-scale, longitudinal investigation of health-related quality of life outcomes in men diagnosed with prostate cancer. Arnold Potosky, PhD, updated the trial’s progress at a quality of life and outcomes symposium sponsored by Northwestern University and Evanston Northwestern Healthcare. CHICAGOIn 1994, the National Cancer Institute began a large-scale, longitudinal investigation of health-related quality of life outcomes in men diagnosed with prostate cancer. Arnold Potosky, PhD, updated the trials progress at a quality of life and outcomes symposium sponsored by Northwestern University and Evanston Northwestern Healthcare. The project team is currently analyzing changes in quality of life after a prostate cancer diagnosis in the study population, said Dr. Potosky, senior investigator in the National Cancer Institutes Division of Cancer Control and Population Science. Ultimately, he expects the findings will be incorporated into clinical practice to assist patients and physicians in making decisions about prostate cancer treatment. The project, known as the Prostate Cancer Outcomes Study, is being conducted by the NCIs Surveillance, Epidemiology, and End Results (SEER) program in collaboration with six SEER cancer registries. The study is designed to determine the prevalence of complications across a large population of men with prostate cancer and provide generalizable results concerning prostate cancer practice patterns. It is measuring variations in care, specific aspects of quality of life, and the influence of comorbid conditions in men with histologically confirmed invasive cancer of the prostate. The objective is to find men soon after diagnosis and follow them over the long term, Dr. Potosky said. To meet this goal, the study used a rapid case ascertainment system that identified men within 6 to 8 weeks of their diagnosis and mailed them a survey that asked about their bowel and bladder symptoms and sexual function 6, 12, and 24 months after their diagnosis. The study also obtains detailed information about the clinical characteristics of the disease and the use of various types of treatment through medical record abstracts from physicians and hospitals. Since the study began, about 3,500 men out of a total identified sample of 5,600 men have completed 6- or 12-month surveys. The racial and ethnic breakdown is approximately 500 non-Hispanic black, 500 Hispanic, and 2,500 non-Hispanic white. The cohort is drawn from six SEER areas (Los Angeles, Utah, Seattle, New Mexico, Atlanta, and Connecticut), and the study population is representative of the population of men with prostate cancer in the SEER areas. Dr. Potosky noted that this is not to say that SEER areas are representative of the country as a whole. The NCI plans to conduct ongoing analyses of the data collected by the study and to publish a newsletter for men who participate in the study to keep them informed of its progress. The Institute also seeks to get the word out about what were doing and get feedback, Dr. Potosky said.",-0.005070564802736
75865db5-1808-48ee-b4fe-2970e6332798,"© 2021 MJH Life Sciences and Cancer Network. All rights reserved. © 2021 MJH Life Sciences and Cancer Network. All rights reserved. QOL and Outcomes Research in Prostate Cancer Patients With Low Socioeconomic Status Adenocarcinoma of the prostate the most common solid tumor in American men, is responsible for tremendous morbidity and mortality in this country, and yet controversy governs most discussions of screening, diagnosis, and treatment. Central to any Adenocarcinoma of the prostate the most common solid tumor in American men, is responsible for tremendous morbidity and mortality in this country, and yet controversy governs most discussions of screening, diagnosis, and treatment. Central to any study of outcomes in prostate cancer must be an examination of health-related quality of life. Toward this end, quality of life research in this area of urologic oncology has rapidly expanded over the last several years. Indeed, when differences in survival cannot be demonstrated among treatments, quality of life may be the deciding factor in difficult choices faced by men with early- or late-stage disease. Prostate cancer exacts a greater human toll in disadvantaged populations, such as poor, underserved, and African-American men. Nevertheless, quality-of-life research focused on this demographic segment of society has been lacking. Although most studies do include some minority patients, they typically make up a small fraction of any study sample. Hence, most of the quality-of-life literature in prostate cancer is drawn from highly educated, affluent population samples obtained from a variety of tertiary academic hospitals in the United States. Although data from these centers have provided an important foundation for a relatively young field, they have largely ignored the patients who often suffer most from the effects of prostate cancer. The article by Kim and colleagues, written under the direction of Dr. Charles Bennett, a well-known prostate cancer outcomes researcher, describes an important initiative aimed at remedying this deficit in the literature. In fact, lessons already learned from the VA Cancer of the Prostate Outcomes Study (VA CaPOS) have made a valuable contribution to the state of knowledge in this discipline, and they promise to unlock many more secrets from an understudied population unduly burdened by prostate cancer. Thus far, several interesting revelations have come to light from research in this special population. First, quality of life and other patient-centered outcomes can be reliably measured in patients of low literacy and socioeconomic status. This confirms that although the methodology must be altered into a more contextually appropriate format, quality-of-life assessments can, in fact, be made in this patient population. Second, participation and response rates are high. This indicates that men of low socioeconomic status have both the interest and the willingness to talk about their physical, emotional, and social responses to illness. Third, as prostate cancer advances, quality-of-life domains are highly responsive to change. As in the majority population, this finding supports the use of quality-of-life measurements as important outcome variables in both clinical and research studies of minority populations. Fourth, utilities for impaired health states, although often difficult to measure in even the most educated subjects, can be assessed and used",-0.0089277857914567
tiiuae_falcon-7b-instruct_116_multimedqa_3,"Prostate cancer is a type of cancer that affects the prostate gland in men. The outcome of prostate cancer depends on a variety of factors, including the stage of the cancer at diagnosis, the size and grade of the tumor, and whether or not the cancer has spread to other parts of the body. With early detection and treatment, the overall outlook for prostate cancer is usually very good. In fact, the survival rates for prostate cancer are among the highest of all types of cancer, with more than 99% of men surviving at least 10 years after diagnosis. Treatment options for prostate cancer depend on the stage of the cancer, as well as the individual's age and overall health. Treatment may involve surgery, radiation therapy, hormone therapy, chemotherapy, or a combination of these approaches. In some cases, the cancer may be monitored closely without immediate treatment, depending on the individual's individual case. In conclusion, the outlook for prostate cancer is generally very good, with more than 99% of men surviving at least 10 years after diagnosis. There are a variety of treatment options available depending on the individual's specific case, and early detection and treatment can greatly improve the overall prognosis.",-0.0118582090362906
meta-llama_Llama-2-7b-chat-hf_116_multimedqa_2,"Prostate Cancer is one of the most frequently diagnosed types of cancer in men worldwide, with an estimated 184,370 new cases reported in the United States alone in 2020 (according to the American Cancer Society). It occurs when abnormal cells in the prostate gland grow out of control and can potentially spread to other parts of the body if left untreated. The following are possible outcomes for prostate cancer patients: \nTreatment Outcomes:\n * Complete Remission: This means that all signs and symptoms of prostate cancer have disappeared after treatment, and there is no evidence of cancer remaining in the body. \n * Partial Remission: Although some cancer may still be present after treatment, there has been at least a partial response, resulting in improved symptoms or shrinkage of tumors. \nProgression-Free Survival (PFS): PFS refers to how long it takes before cancer grows back after initial treatment begins. The median PFS for localized prostate cancer varies depending on factors such as age and Gleason score (a grading system used by doctors to assess aggressiveness), but generally ranges between two and ten years. However,\npfs rates vary widely across different patient populations; it's essential to consult your doctor regarding individual circumstances. \nOverall Survival Rate (OS): OS measures the average time from diagnosis until death due to any cause - not just disease progression. According to data collected through SEER (Surveillance Epidemiology End Results) program, which tracks cancer incidence nationwide among people aged 20+ years old during 1999-2020 period, overall survival rate five years post-diagnosis was approximately 75% among all newly diagnosed prostate cancer patients combined within this dataset range (using 2019-2020 numbers). Again though,this statistic also relies upon several variables like age at diagnosis,Gleason score etcetera., so talking directly with physician will provide more personalized perspective on expected longevity given specific situation.In addition : \n Quality Of Life (QOL) : While we cannot predict exact QoL scores prior to therapy initiation because these fluctuate based on many individual elements throughout therapy duration — including side effects from medications taken",-0.0149991102516651
ff1ad3f1-a1cd-4289-8bc4-03a910fb4fdf,"Prostate cancer: Case volume and improved outcomes across cancer care (2016). Prostate cancer: Case volume and improved outcomes across cancer care. , (4), 186-187. Prostate cancer : Case volume and improved outcomes across cancer care. / In: , Vol. 13, No. 4, 01.04.2016, p. 186-187. 2016, 'Prostate cancer: Case volume and improved outcomes across cancer care', , vol. 13, no. 4, pp. 186-187. . Prostate cancer: Case volume and improved outcomes across cancer care. . 2016 Apr 1;13(4):186-187. / Prostate cancer : Case volume and improved outcomes across cancer care. In: . 2016 ; Vol. 13, No. 4. pp. 186-187. title = ""Prostate cancer: Case volume and improved outcomes across cancer care"", author = ""Narang, {Amol K.} and Tran, {Phuoc T.}"", note = ""Copyright: Copyright 2017 Elsevier B.V., All rights reserved."", T2 - Case volume and improved outcomes across cancer care N1 - Copyright: Copyright 2017 Elsevier B.V., All rights reserved. UR - http://www.scopus.com/inward/record.url?scp=84956910925&partnerID=8YFLogxK UR - http://www.scopus.com/inward/citedby.url?scp=84956910925&partnerID=8YFLogxK Powered by , & © 2021 ""We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the",-0.0186019651591777
04f7c426-9f1b-49ba-840a-e8df42d73a84,"Scottish Researchers Develop Prostate Cancer Checklist to Help Patients Weigh Treatment Options Click here to subscribe to the Prostate Cancer News Today Newsletter! Prostate cancer patients and their doctors can now get enhanced guidance on treatment options and consequences, thanks to a new checklist developed by researchers at Scotland's University of Aberdeen. As described in their study, “A core outcome set for localised prostate cancer effectiveness trials,” which appeared in BJU International, the checklist covers the 19 most important core outcomes when evaluating possible treatments. It is likely to be useful to medical professionals seeking to ""decode"" the results of current prostate cancer medical trials, which might translate into better assistance when deciding which treatments would benefit their patients. The three-year systematic review that led to creation of the checklist received funding from Cancer Research Aberdeen and North East Scotland (CRANES). It included reviews of hundreds of prostate cancer trials worldwide. Surprisingly, the study found dozens of distinct ways to define and measure the same outcomes, making it difficult to compare and contrast various findings. ""At the moment, we are effectively comparing apples and oranges when it comes to prostate cancer studies,"" Thomas Lam, chief investigator and an honorary senior clinical lecturer at the University of Aberdeen, said in a press release. ""Some studies only look at incontinence, some look only at erectile dysfunction, others will look at different outcomes, and they often have different scales of success and failure. As a result it is incredibly difficult for patients and surgeons to make informe or to access all post and page content. Tagged , , , , . Introducing Our Fantastic ‘Prostate Cancer News Today’ Columnist Adding Zytiga, Prednisone to ADT Improves Outcomes for Newly Diagnosed, High-risk Metastatic Prostate Cancer Patients Nubeqa Prescribing Information Updated With New Survival Data Orgovyx Now Available in US for Advanced Prostate Cancer Oral ARV-110 Shows Promise in Heavily Treated mCRPC Patients FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials Relugolix Granted FDA Priority Review as New Treatment Type U.K. Study to Examine Genetic Screening for Large Prostate Cancer Population Visit Prostate Cancer News Today's profile on Pinterest. 3 W Garden St Suite 700 Pensacola, FL 32502 Email: Phone: Prostate Cancer News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Copyright © 2013-2021 Proudly powered by Binder PRO Theme by to enhance your experience on our website.",-0.0347842872142791
4653ba57-820b-423c-a7f9-e2dd09786a48,"Functional Outcomes Similar Across Localized Prostate Cancer Treatments (HealthDay News) — Most functional differences associated with contemporary management of localized prostate cancer attenuate by five years, according to a study published in the Jan. 14 issue of the . Karen E. Hoffman, M.D., from University of Texas MD Anderson Center in Houston, and colleagues compared functional outcomes associated with prostate cancer treatments over five years after treatment using data from five Surveillance, Epidemiology and End Results Program sites and a U.S. prostate cancer registry. The analysis included 1,386 men with favorable-risk and 619 men with unfavorable-risk prostate cancer. The researchers found that for men with favorable-risk prostate cancer, nerve-sparing prostatectomy was associated with worse urinary incontinence at five years and sexual function at three years versus active surveillance. Low dose-rate brachytherapy was associated with worse urinary irritative, sexual, and bowel function at one year versus active surveillance. While external beam radiation therapy (EBRT) was associated with urinary, sexual, and bowel function changes, they were not clinically different from active surveillance at any time point through five years. For men with unfavorable-risk disease, EBRT with androgen deprivation therapy was associated with lower hormonal function at six months and bowel function at one year but better sexual function at five years and better incontinence function at each time point through follow-up versus prostatectomy. “These estimates of the long-term bowel, bladder and sexual function after treatment may clarify expectations and enable men to make informed choices about care,” the authors write. One author disclosed financial ties to the pharmaceutical industry. Abstract/Full Text (subscription or payment may be required) Overall Survival in mCRPC Cases Linked to Number of Radium-223 Doses CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients. Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions. Copyright © 2020 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s and .",-0.0371478423476219
gpt2-large_116_multimedqa_4,"The results of our research indicate that more than 90% of men with prostate cancer will recover with treatment. In addition, there is no evidence of a higher risk for recurrence in the first year after diagnosis. However, it is important to remember that you have an individualized plan of action based on your specific symptoms, history, age, and genetic makeup that may include certain lifestyle changes. You should also consult your physician or other health care professional before changing anything in your routine. If you choose not to participate in the study and would like to learn more about this, please contact us at [email protected].",-2.841186761856079
gpt2-xl_116_multimedqa_8,"Prostate Cancer is the most common malignancy among men in the United States, affecting more than 2 million men annually. The prognosis for these patients is extremely poor with a median survival time of less than 10 years.\r \r Q: What is the difference between benign prostatic hyperplasia (BPH) and prostatitis?\nAnswer: BPH is characterized by symptoms such as frequent urination and frequent or painful urination that do not affect sexual function. There is no evidence that this condition causes any impairment in healthy men. However, some research suggests it may be linked to an increased risk of developing testicular cancer.\r \r Q: Which drugs can cause prostate cancer? Answer: Prostate cancer is thought to occur when tumors break down certain proteins found in the gland. When these protein molecules become carcinogenic they migrate throughout the body where they form new tumors. Several types of drug have been linked to prostate cancer including: radiation therapy; agents used to treat diabetes; and chemotherapy. Other possible agents include hormone replacement therapy, marijuana and alcohol use. \r \r For more information on the different forms of breast cancer please visit www.cancer.org/breast/. For more information on other types of cancer visit http://www.cancer.gov/about_cancer/.",-6.085330486297607
gpt2_116_multimedqa_7,"yes Cancer Prevention & Treatment of Cancer [ edit ] A large body (over 25 million) study has identified the role played by multiple environmental factors in determining risk for advanced disease progression across most cancers as well into adulthood.[9] The effects of one or more conditions on individual's prognosis were investigated using three different cohort studies at various stages of their life - from early onset until death;[10][11], including postmortem tissue growth,[12];<1% per year after initial treatment with chemotherapy against human breast carcinoma cells that had developed over two decades prior to autopsy:[13],[14]] After five years following tumorigenesis therapy alone exposure was less predictive than when combined within several months before diagnosis due either reduction in number of tumors resulting during follow-up surgery(s), increased probability of metastasis which resulted in reduced survival rate amongst those who completed chemo only compared w/ no increase overall mortality rates among non-chemotherapy patients under 6 mo duration since date of original assessment*[/15]. In addition, there is evidence associating an immune response associated immunological processes such like HapMap activation along each cell line contributing significantly to premature development even without preclinical screening results where these proteins have been implicated.(17) Some observational research indicates increasing incidence of ovarian hyperplasia based upon analysis between age 3–6 y whereas others show decreased prevalence according theretoinofovaginal histology comparing male vs female controls while other analyses suggest very small numbers but lower levels relative not having known ovulation complications despite adequate imaging criteria.* When considered through genetic testing it becomes clear what mechanisms predisposes individuals towards developing many types possible reproductive problems related infertility can lead to subsequent loss rather then success because both endocrine disruption may play significant roles affecting function independent tissues involved include bone marrow, kidney organs,, brain regions.. These findings provide insights regarding this important issue given its relevance beyond just cytogenetic disorders...."" This article outlines our current understanding of how certain gene expression modulates some genes leading them to develop additional symptoms unrelated solely ot oogenesis causing changes elsewhere called epigenetically induced chromosomal abnormalities.""The present review evaluates previous molecular observations concerning all manner eumeral markers showing varying frequency dependent influence thereof via transcriptional regulation ""with respect generally being found highly correlated genotype level.... Many authors also propose numerous etiological pathways influencing potential pathologies depending upon specific loci."" However however none seem interested except perhaps if they use DNA modification methods i).DNA modifications do vary widely Among recent discoveries we know alot here : that any set up you would want your",-12.584064483642578
gpt2-medium_116_multimedqa_5,The treatment is effective for reducing the rate of recurrence in both men with or without testicular carcinoma; however it does not improve survival rates as much if you have an untreated disease that develops during your lifetime,-12.69204330444336
